-
Mashup Score: 9Low-Dose Azacitidine Plus Venetoclax Is Effective Maintenance for AML | Blood Cancers Today - 7 day(s) ago
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction therapy.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
Cellular therapies are an effective option in hematologic malignancies but have been slower to develop in AML, but identifying new targets paves the way for evolving treatments.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Cellular therapies have emerged as effective treatments for hematologic malignancies, yet progress in applying them to #AML lags behind. However, identifying new targets is driving innovation. @Daver_Leukemia @MusaYilmazMD @MDAndersonNews @StJudeResearch https://t.co/4qm32wr2l8 https://t.co/8ArowVHKCr
-
-
Mashup Score: 3MRD Appears Optimal for Allogeneic Transplant Patient Selection in AML | Blood Cancers Today - 8 day(s) ago
MRD status after induction chemotherapy predicted benefit from allogeneic transplant in patients with NPM1-mutated AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
✅ MRD status after induction chemotherapy predicted benefit from allogeneic transplant in patients with NPM1-mutated #AML in first complete remission. Read more about the study, led by Jad Othman, MD, of @NthSydHealth, and published in @BloodJournal. 📖 https://t.co/xsjpO0uU7A https://t.co/PXLrcYMRpy
-
-
Mashup Score: 3My ‘Other Birthday’ is Coming Up After Cancer - 11 day(s) ago
What it’s like having a “second birthday” after receiving a bone marrow transplant for my AML.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Novel Duplex Sequencing Assay Improves Detection of MRD in AML | Blood Cancers Today - 11 day(s) ago
The novel DuplexSeq AML-XP next-generation sequencing assay was highly accurate for detecting MRD in AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Acute Myeloid Leukemia | Blood Cancers Today - 13 day(s) ago
Acute myeloid leukemia (AML), the most common acute leukemia in adults, can occur when myeloid cells form abnormal myeloblast instead of developing into normal mature blood cells.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 5Novel AML Therapy, Pivekimab Sunirine, Shows Promising Anticancer Activity | Blood Cancers Today - 23 day(s) ago
Monotherapy with pivekimab sunirine demonstrated activity in patients with relapsed or refractory CD123-positive AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet-
The novel therapy pivekimab sunirine demonstrated promising anticancer activity in patients with relapsed or refractory CD123-positive #AML, according to a study led by @Daver_Leukemia, of @MDAndersonNews, and published in @TheLancetOncol. 📰 Learn more: https://t.co/e71I6SFHp6 https://t.co/NKobx4uGLw
-
-
Mashup Score: 4ASTX727 Plus Venetoclax Is a Safe Regimen in Older Patients With AML | Blood Cancers Today - 26 day(s) ago
The ORR was 64% in the frontline cohort and 46% in the relapsed or refractory cohort.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5Novel AML Therapy, Pivekimab Sunirine, Shows Promising Anticancer Activity | Blood Cancers Today - 1 month(s) ago
Monotherapy with pivekimab sunirine demonstrated activity in patients with relapsed or refractory CD123-positive AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet-
The novel therapy pivekimab sunirine demonstrated promising anticancer activity in patients with relapsed or refractory CD123-positive #AML, according to a study led by @Daver_Leukemia, of @MDAndersonNews, and published in @TheLancetOncol. 📰 Learn more: https://t.co/e71I6SFHp6 https://t.co/NKobx4uGLw
-
-
Mashup Score: 6Is Gilteritinib Effective as Post-Transplant Maintenance in Patients With FLT3-ITD-Mutated AML? | Blood Cancers Today - 1 month(s) ago
These prospective results establish FLT3-ITD mutations as essential markers of MRD, the authors wrote.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
🙌 Low-dose azacitidine plus venetoclax was found to be an effective maintenance strategy for #AML, according to a study led by Alexandre Bazinet, MD, of @MDAndersonNews and published in @TheLancetHaem. 📖 https://t.co/bsoSVpMFyh https://t.co/CtJOknFp0a